Quick Answer: Retatrutide is an investigational weight loss drug from Eli Lilly that targets three hormone receptors (GLP-1, GIP, and glucagon) one more than Mounjaro and two more than Ozempic
No planning, no shopping, no guessing
Cardiovascular outcome trials (CVOTs) of GLP-1RAs To date, the REWIND study has demonstrated for the first time that primary cardiovascular prevention strategies can significantly reduce cardiovascular adverse events in patients with T2DM, regardless of whether or not these patients are co-diagnosed with CVD [23]
The app sets personalized targets based on your goals, though I found the calorie targets too low for very active people
There are so many new medications available, how do you know where to start
The goal is not to replace one intervention with another